NEW YORK and SUNNYVALE,
Calif., May 17, 2021 /PRNewswire/
-- VG Acquisition Corp. (NYSE: VGAC), a special purpose
acquisition company sponsored by Virgin Group, today announced that
the date of its extraordinary general meeting of shareholders to
vote on its proposed business combination with 23andMe, Inc., a
leading consumer genetics and research company, will be
June 10, 2021. Shareholders of
record as of the close of business on May 5,
2021 are entitled to vote on matters that come before the
extraordinary general meeting. The business combination, if
approved by VGAC's stockholders, is expected to close as soon as
practicable following the extraordinary general meeting. Upon the
closing, VGAC will change its name to 23andMe Holding Co. ("New
23andMe"), and New 23andMe's shares and warrants are expected to
trade on the Nasdaq under the new ticker symbols "ME" and "ME WS",
respectively.
A definitive proxy statement and other relevant documents will
be mailed to shareholders of VGAC as of May
5, 2021. Shareholders are encouraged to read the proxy
statement and accompanying documents in their entirety.
Shareholders can also obtain copies of the proxy statement, without
charge, by directing a request to: VG Acquisition Corp. 65 Bleecker
Street, 6th Floor, New York NY
10012. These documents and VGAC's annual and other reports filed
with the SEC can also be obtained, without charge, at the SEC's
internet site (https://www.sec.gov).
Shareholders of VGAC are encouraged to submit their vote as soon
as possible to ensure they are represented at the extraordinary
general meeting. VGAC has engaged Morrow Sodali LLC ("Morrow
Sodali") as its proxy solicitor in connection with the
extraordinary general meeting. Shareholders needing
assistance in voting their VGAC shares can contact Morrow Sodali by
calling (800) 662-5200, or banks and brokers can call collect at
(203) 658-9400, or by emailing
vgac.info@investor.morrowsodali.com.
About 23andMe
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading
consumer genetics and research company. Founded in 2006, the
company's mission is to help people access, understand, and benefit
from the human genome. 23andMe has pioneered direct access to
genetic information as the only company with multiple FDA
authorizations for genetic health risk reports. The company has
created the world's largest crowdsourced platform for genetic
research, with 80% of its customers electing to participate. The
23andMe research platform has generated more than 180 publications
on the genetic underpinnings of a wide range of diseases,
conditions and traits. The platform also powers the 23andMe
Therapeutics group, currently pursuing drug discovery programs
rooted in human genetics across a spectrum of disease areas,
including oncology, respiratory, and cardiovascular diseases, in
addition to other therapeutic areas. More information is available
at www.23andMe.com.
About VG Acquisition Corp.
VG Acquisition Corp. was formed for the purpose of effecting a
merger, amalgamation, share exchange, asset acquisition, share
purchase, reorganization, or similar business combination with one
or more businesses. The management team includes Sir Richard Branson, founder of VGAC, a renowned
global entrepreneur, and founder of the Virgin Group; Josh Bayliss, VGAC's Chief Executive Officer and
director, who is the Chief Executive Officer of the Virgin Group
and is responsible for the Virgin Group's strategic development,
licensing of the brand globally, and management of direct
investments on behalf of the Virgin Group in various companies
around the world; and Evan Lovell,
VGAC's Chief Financial Officer and director, who is the Chief
Investment Officer of the Virgin Group and is responsible for
managing the Virgin Group's investment team and portfolio in
North America. More information is
available at https://vgacquisition.com/
Forward-Looking Statements
This communication contains certain "forward-looking statements"
including statements regarding the anticipated timing of the
business combination (the "Transaction") between VGAC and 23andMe.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intends," "may," "might," "plan," "possible,"
"potential," "predict," "project," "should," "would," and similar
expressions may identify forward looking statements, but the
absence of these words does not mean that a statement is not
forward looking. The forward-looking statements contained herein
are based on VGAC's current expectations and beliefs concerning
future developments and their potential effects, but there can be
no assurance that these will be as anticipated. These
forward-looking statements involve a number of risks, uncertainties
(some of which are beyond the control of VGAC), or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements. These factors include, among others:
the inability to complete the Transaction, including due to the
failure to receive required security holder approvals, or the
failure of other closing conditions. Except as required by law,
VGAC does not undertake any obligation to update or revise any
forward-looking statements whether as a result of new information,
future events, or otherwise.
Additional Information
This communication does not constitute an offer to sell or the
solicitation of an offer to buy any securities, or a
solicitation of any vote or approval, nor shall there be any sale
of securities in any jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such
jurisdiction.
Participants in the Solicitation
VGAC, 23andMe, and their respective directors, executive
officers, other members of management, and employees may be deemed
to be participants in the solicitation of proxies from VGAC's
shareholders in connection with the Transaction. Information
regarding the names and interests in the proposed transaction of
VGAC's directors and officers is contained in VGAC's filings with
the SEC. Additional information regarding the interests of such
potential participants in the solicitation process is also included
in the registration statement (and in the definitive proxy
statement/prospectus) and other relevant documents filed with the
SEC.
Contacts
Investor Relations:
23andMe
Sard Verbinnen & Co
23andMe-SVC@sardverb.com
VG Acquisition Corp.
FTI Consulting
US, Canada, South America, Australia – Antonia
Gray / Grace Altman
Antonia.Gray@fticonsulting.com / Grace.Altman@fticonsulting.com
UK, Middle East, Asia, Africa
– Charles Palmer
Charles.Palmer@fticonsulting.com
Media Relations:
23andMe
press@23andMe.com
Sard Verbinnen & Co
Paul Kranhold / John Christiansen / Chris Kittredge
23andMe-SVC@sardverb.com
VG Acquisition Corp.
FTI Consulting
US, Canada, South America, Australia – Antonia
Gray / Grace Altman
Antonia.Gray@fticonsulting.com / Grace.Altman@fticonsulting.com
UK, Middle East, Asia, Africa
– Charles Palmer
Charles.Palmer@fticonsulting.com
View original
content:http://www.prnewswire.com/news-releases/virgin-groups-vg-acquisition-corp-announces-date-of-shareholders-meeting-in-connection-with-its-pending-business-combination-with-23andme-301292415.html
SOURCE VG Acquisition Corp.